Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Advanced
  • Histone deacetylase inhibitors...
  • Cite this
  • Text this
  • Email this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Permanent link
Export Ready — 
Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?

Bibliographic Details
Main Authors: Fernanda Faião-Flores, Keiran SM Smalley
Format: Article
Language:English
Published: Taylor & Francis Group 2019-12-01
Series:Melanoma Management
Subjects:
clinical trials
endothelin
HDAC inhibition
IGF1R
MEK inhibition
plasticity
Online Access:https://www.futuremedicine.com/doi/10.2217/mmt-2019-0017
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://www.futuremedicine.com/doi/10.2217/mmt-2019-0017

Similar Items

  • Intermittent MEK inhibition for the treatment of metastatic uveal melanoma
    by: Shaheer Khan, et al.
    Published: (2022-09-01)
  • Inhibitors of histone deacetylase 6 based on a novel 3-hydroxy-isoxazole zinc binding group
    by: Pasquale Linciano, et al.
    Published: (2021-01-01)
  • Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant <it>BRAF</it> and wildtype <it>PTEN</it> status
    by: Byron Sara A, et al.
    Published: (2012-10-01)
  • Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma
    by: Emily J. Lelliott, et al.
    Published: (2021-05-01)
  • Acquired vulnerability against EGF receptor inhibition in gastric cancer promoted by class I histone deacetylase inhibitor entinostat
    by: Tamara Zenz, et al.
    Published: (2025-02-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs